問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

1593Cases

2011-07-01 - 2013-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Study ended11Sites

2015-06-01 - 2017-12-30

Phase II

An Open-Label, Phase II Study to Evaluate SCB01A in Patients with Recurrent or Metastatic Squamous Cell Head and Neck Cancer who have Received Platinum-Based Treatment

  • Condition/Disease

    Squamous Cell Head and Neck Cancer

  • Test Drug

    SCB01A

Participate Sites
6Sites

Terminated6Sites

2019-10-01 - 2020-12-30

Phase II

A Phase 2a open-label study of the oral Farnesoid X Receptor (FXR) modulator EYP001a to assess its safety and anti-viral effect in chronic Hepatitis B (CHB) patients in combination with pegylated interferon alpha2a (peg-IFN) alone and with entecavir (ETV)

  • Condition/Disease

    chronic Hepatitis B

  • Test Drug

    EYP001a

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2020-02-28 - 2022-12-31

Phase II

A Phase 2, open-label study of orally administered PAX-1 therapy in patients with brain metastases secondary to non-small cell lung cancer

  • Condition/Disease

    Brain metastases secondary to non-small cell lung cancer

  • Test Drug

    PAX-1

Participate Sites
8Sites

Recruiting8Sites

2022-11-01 - 2024-09-30

Phase I

An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

  • Condition/Disease

    Leukemia, Myeloid, Acute

  • Test Drug

    H3B-8800 (RVT-2001)

Participate Sites
5Sites

Recruiting5Sites

2013-11-15 - 2019-12-31

Phase II

A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of CSTC1 in Patient with Diabetic Foot Ulcers

  • Condition/Disease

    Diabetic Foot Ulcers

  • Test Drug

    CSTC1

Participate Sites
3Sites

Terminated3Sites

2011-02-01 - 2013-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2010-11-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2021-11-01 - 2022-04-29

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2019-10-31 - 2022-02-04

Phase II

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-53718678 in Adult and Adolescent Hematopoietic Stem Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract.

  • Condition/Disease

    Respiratory Syncytial Virus Infections

  • Test Drug

    JNJ-53718678

Participate Sites
4Sites

Suspended4Sites

1 103 104 105 106 107 160
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB